logo
Uncertainty around NIH funding leaves Alzheimer's studies in limbo

Uncertainty around NIH funding leaves Alzheimer's studies in limbo

Yahoo24-04-2025

Zahydie Burgos Ribot and her husband, Francisco Rios, are checking items off their travel bucket list and spending quality time together before Francisco will no longer be able to travel – and before his brain forgets.
The Florida-based couple recently crossed Alaska off the list. Their next trip will be to Niagara Falls.
'We have a whole schedule,' Ribot said. 'We're choosing to live every single day with a lot of intention.'
That's because they know that Rios' window to easily create new memories is closing. About three years ago, at age 46, he was diagnosed with early-onset Alzheimer's disease.
Although Rios has been doing well on a new treatment he receives through a clinical trial, Ribot is increasingly afraid that the study could be hindered by cuts to federal funding of biomedical research.
The Trump administration has been conducting a restructuring of the US Department of Health and Human Services as well as a review of funding, resulting in the abrupt cancellation of hundreds of research grants under the National Institutes of Health and many others left in limbo, waiting for a decision on whether their funding will be renewed.
In March, 14 of 35 Alzheimer's Disease Research Centers had their funding halted by the NIH as the administration stopped $65 million in funding for research, according to Democratic lawmakers.
CNN has contacted HHS and the White House for comment.
'This is alarming, because these are critical data that inform not only prognosis but inform trajectory of the disease and inform future treatments,' Ribot said.
Rios also has been following these developments and remains worried about his future.
'He just asked me, 'Am I going to continue getting the trial?' But he was crying and literally ripping the skin off his fingers because of the anxiety,' Ribot said. 'He knows what's at stake. He is aware. He wants to continue the medication.'
Rios has been participating in a clinical trial conducted by Washington University in St. Louis in which he has been receiving the Alzheimer's drug Leqembi paired with an experimental therapy called E2814, given as intravenous infusions, to help slow his Alzheimer's symptoms.
Ribot credits the trial with helping curb Rios' memory loss and cognitive decline.
Before Rios was diagnosed, he began to emotionally withdraw and disconnect from loved ones. He even got lost while driving to a routine doctor's appointment about 10 minutes from their home, Ribot said.
She initially thought he was showing signs of depression. But Rios' doctor realized that something else was happening in his brain and referred him to the Young-Onset Dementias Clinic at Johns Hopkins in Baltimore.
'They ran more tests, and they ran the genetic testing, and that's when we had the final confirmation that it was Alzheimer's,' Ribot said.
If funding for Rios' clinical trial is curtailed, she said, not only could he and the other participants lose access to the medications that they hope are giving them more time to live normally, the development of other impactful Alzheimer's treatments could be delayed.
About a dozen Alzheimer's disease research centers are still waiting for their federal funding to be renewed, said Dr. Michael Greicius, professor of neurology and neurological sciences at the Stanford University School of Medicine, whose Alzheimer's center is among those awaiting a decision.
'Our five-year renewal was reviewed in October. Normally, we would have gotten a decision probably around February,' he said, adding that research funding for his team at the Stanford Alzheimer's Disease Research Center ran out about three weeks ago.
'It seems like we're moving towards renewal, but it's very hard to read the tea leaves, and that makes it really challenging when you're thinking about projects you'd like to undertake or hiring new research coordinators, for example,' he said.
Greicius and his colleagues had to hold off on starting research projects because they didn't know whether there will be funding coming in, he said.
The uncertainty around funding baffles him.
'It's hard to imagine a less political topic than Alzheimer's disease. I mean, it affects people from red states and blue states and purple states. It's so common. Almost everyone either has a relative in their family or at least has a friend who has a relative that's been affected by Alzheimer's disease,' Greicius said.
'It still seems like the easiest-to-agree-upon target for federally funded research, and yet it's not at all clear that this progress is going to continue,' he said. 'That, for me, is a large part of the frustration – just the uncertainty of it all.'
Preventive neurologist Dr. Richard Isaacson, founder of one of the first Alzheimer's prevention clinics in the United States, is also waiting to see whether his federal grants will be renewed.
'We're somewhere between limbo and purgatory,' he said.
Isaacson, who directs research at the Institute for Neurodegenerative Diseases in Florida, has developed free online software called RetainYourBrain, which aims to democratize access to brain health care. Users input their risk factors for Alzheimer's and receive a personalized risk assessment, as well as personalized recommendations and time-sensitive reminders on how to improve their brain health.
But without continued funding, 'it may never be released to the public,' Isaacson said.
Supporters of the funding cuts argue that the nation should reduce 'wasteful spending' and prioritize efficiency.
'With the government wanting to cut back on spending money, I get it. But Alzheimer's is one of the most expensive diseases to our health care system,' Isaacson said.
It's estimated that nearly 1 in every 6 Medicare dollars was spent on someone with the disease last year, according to the Alzheimer's Association, and the average per-person Medicare spending for older adults with Alzheimer's is estimated to be 2.8 times higher than average per-person spending for all other seniors.
'I feel that cutting Alzheimer's research that may save money over time, and doing it rapidly, is a bad investment,' Isaacson said.
While some studies are waiting to see if they'll continue, some studies have already had to take steps to shut down.
When the NIH canceled grants in March related to diversity, equity and inclusion, or DEI, some Alzheimer's studies were swept up in the consequences.
Federal funding for a multiyear study at the University of California, Davis' Alzheimer's Disease Research Center was abruptly terminated. This led the center's co-director, Dr. Charles DeCarli, to issue an appeal and fight to have the grant fully reinstated.
'The appeal had to be done within 30 days, and in the meantime, we had to shut down the study. So while I was working on the appeal, my team was doing all the things that closing a study needs to involve, which is hundreds of hours of work, notifying the 33 sites in this study,' he said.
DeCarli's appeal was successful. He won that battle but is still recovering from the turmoil.
'It was a very challenging month in my life,' DeCarli said. 'It just seems to me that the only reason that this was terminated is because it includes the word 'diverse' in the title.'
The study, titled 'The Clinical Significance of Incidental White Matter Lesions on MRI Amongst a Diverse Population with Cognitive Complaints (INDEED),' involves examining the effect that white matter injury in the brain and vascular issues may have on cognitive performance as well as health outcomes. The research was being funded by the NIH's National Institute of Neurological Disorders and Stroke.
Up to 25% of people who develop dementia later in life may have some type of vascular contributing factor to their disease, and DeCarli said his study could help 'lay out the foundation' for diagnostic tests and treatments for them.
'When these studies are terminated, an opportunity is lost to advance science,' he said.
Other studies may face similar threats to funding. According to a policy notice issued Monday, the NIH said it will begin pulling medical research funding from universities with diversity and inclusion programs and any boycotts of Israeli companies.
The agency 'reserves the right to terminate financial assistance awards and recover all funds' if grant recipients do not comply with federal guidelines barring diversity and equity research and 'prohibited boycotts,' the notice said.
The policy applies to 'domestic recipients of new, renewal, supplement, or continuation awards that are issued on or after' April 21, according to the notice.
Separately, the Washington-based nonprofit UsAgainstAlzheimer's has been tracking previously terminated grants and the funding cuts at the NIH that took place in March and earlier this month, and it warns that some cuts could stall the progress being made to find a cure for Alzheimer's disease.
'In the last 10 years, there have been groundbreaking advances in Alzheimer's disease research, in understanding where the disease comes from, and understanding how to diagnose the disease, and ultimately in how to treat the disease. But we don't have a cure yet,' said Russ Paulsen, chief operating officer at UsAgainstAlzheimer's.
'In looking through the list of grants that have been affected, it appears to cut across prevention, diagnosis, treatment and ultimately seeking a cure, as well as understanding the basics of the disease to start with,' he said. 'We've made huge progress, and now is not the time to take our foot off the accelerator.'
In the meantime, Ribot and Rios are trying to keep their heads up. They are keeping an eye on any new developments in research funding cuts while continuing to focus on their travel bucket list.
'While he's here and we're here, we're living our life. We are finding joy. Even when we cry, we laugh. Even when we are in despair, we have hope,' Ribot said.
'I'm not going to romanticize this disease, because that's not it – but there's still purpose and meaning and joy,' she said. 'We're not going to let this disease rob us of our present.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension

Yahoo

time15 minutes ago

  • Yahoo

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension

NORCROSS, Ga., June 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it will host a virtual key opinion leader (KOL) event on Monday, June 16, 2025 at 12:00 PM ET. To register, click here. The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include: Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell Biology and Physiology, & Director of Terance Kahn Liver Research Program, Indiana University School of Medicine; and Naim Alkhouri, MD, FAASLD, DABOM, Chief Academic Officer, Summit Clinical Research, & Director of the Steatotic Liver Program, North Shore Gastroenterology, Cleveland, OH. The event will highlight results from Galectin's NAVIGATE Phase 3 clinical trial evaluating belapectin for the treatment of MASH cirrhosis and portal. Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of MASH and fibrosis. With no approved therapies to prevent or treat varices in MASH cirrhosis, belapectin may represent the first potential treatment to address this significant unmet need. A live question and answer session will follow the formal presentations. About Naga P. Chalasani, MD Naga P. Chalasani, MD completed medical school in India before he moved to the US to pursue Internal Medicine residency at Emory University in Atlanta, followed by a fellowship in Gastroenterology and Hepatology at the same institution. He joined IU in 1997 as an Assistant Professor in the Division of Gastroenterology and Hepatology. Dr. Chalasani is currently David W. Crabb Professor of Gastroenterology and Hepatology and Adjunct Professor of Anatomy, Cell Biology & Physiology and as Director of Terance Kahn Liver Research Program at Indiana University School of Medicine. He previously served as the GI Division Chief (2007-2020), Associate Dean for Clinical Research (2017-2020) interim Chair of the Department of Medicine (2020-2021) and Vice President for Academic Affairs at Indiana University Health (2022-2024). He is a highly regarded clinician and ranked as Top Doctor continuously for over 15 years. He has been continuously funded by the National Institutes of Health (NIH) since 1999 and is currently the PI on several U01 and R01 awards from the NIH. Dr. Chalasani is considered an authority in the fields of Non-Alcoholic Fatty Liver Disease (NAFLD) and Drug Induced Liver Injury (DILI), two highly significant public health problems. He is one of the most published and most cited investigators at Indiana University, with Google Scholar H-Index 120 and 75,000 citations (as of Feb 2025). He is an elected member of the American Society of Clinical Investigation (ASCI), the American Association of Physicians (AAP) and the National Academy of Medical Sciences – India (2024). He has mentored over 75 undergraduate and graduate students, medical students, sub-specialty trainees, and junior faculty. Twenty of his mentees are recipients of federal funding (K award, U01, R21, R01, DOD, and VA Merit Review). To honor his contributions and mentorship, Naga P Chalasani Endowed Professor in Gastroenterology and Hepatology has been established at Indiana University School of Medicine in October 2022. About Naim Alkhouri, MD, FAASLD, DABOM Naim Alkhouri, MD, FAASLD, DABOM is the Chief Academic Officer at Summit Clinical Research and the Director of the Steatotic Liver Program at North Shore Gastroenterology in Cleveland, OH. Prior to joining Summit, Dr. Alkhouri served as the Chief Medical Officer and Director of the Steatotic Liver Disease program at Arizona Liver Health in Phoenix, AZ. Dr. Alkhouri is a key opinion leader in the field of MASH therapeutics and an advisor/ consultant to many pharmaceutical and biomarker development companies. He is Principal Investigator on several multicenter global MASH trials and a member of the AASLD MASLD Special Interest Group (MASLD SIG). Dr. Alkhouri has been published in over 260 publications to include publications in the New England Journal of Medicine, Lancet, JAMA, Nature Medicine, Gastroenterology, Hepatology, and Journal of Hepatology. He presents his work at both national and international medical conferences. About Galectin Therapeutics Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as 'may,' 'estimate,' 'could,' 'expect', 'look forward', 'believe', 'hope' and others. They are based on management's current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that Galectin's development program for belapectin will lead to the first therapy for the treatment of MASH, formerly known as NASH, with cirrhosis and those regarding the hope that our lead compounds will be successful in cancer immunotherapy and in other therapeutic indications. Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements include, among others, full analysis of the NAVIGATE trial data may not product positive data; Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of belapectin or any of its other drugs in development; the Company may not be successful in scaling up manufacturing and meeting requirements related to chemistry, manufacturing and control matters; the Company's current clinical trial and any future clinical studies may not produce positive results in a timely fashion, if at all, and could require larger and longer trials, which would be time consuming and costly; plans regarding development, approval and marketing of any of Galectin's drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies; regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials. Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations. For a discussion of additional factors impacting Galectin's business, see the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements. Company Contact:Jack Callicutt, Chief Financial Officer(678) 620-3186ir@ Investor Relations Contact:Kevin Gardnerkgardner@ Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics' galectin-3 inhibitor belapectin.

Organic Payment Gateways' CEO Highlights Demand for Webflow Healthcare Payment Integrations
Organic Payment Gateways' CEO Highlights Demand for Webflow Healthcare Payment Integrations

Yahoo

time29 minutes ago

  • Yahoo

Organic Payment Gateways' CEO Highlights Demand for Webflow Healthcare Payment Integrations

SCARBOROUGH, Maine, June 10, 2025 /PRNewswire/ -- Alex Roy, CEO of Organic Payment Gateways, a leader in specialized payment solutions, today announced the launch of a new, tailored payment processing service designed specifically for healthcare practices built on the Webflow platform. This innovative offering directly addresses the significant challenges faced by healthcare providers, online pharmacies, and telemedicine service providers who have experienced payment rejections or declines from traditional processors such as Square, Stripe, or PayPal. The initiative responds to the increasing adoption of Webflow within the telehealth industry, providing a much-needed, reliable avenue for credit card transactions. Healthcare businesses often navigate a complex landscape when it comes to payment acceptance. The nature of their services, which can include prescriptions and virtual consultations, sometimes leads to their designation as "high-risk" by mainstream payment providers. This can result in frequent transaction declines, disruption of operations, and impacts on revenue stability. Organic Payment Gateways' new service is engineered to overcome these hurdles, ensuring that Webflow-based online healthcare entities can process credit card payments seamlessly and securely, fostering uninterrupted service delivery and consistent cash flow. The new service is built for the Webflow ecosystem, recognizing the platform's growing prominence in the digital health sector. It delivers a stable merchant account and payment gateway solution, featuring a critical, tested third-party integration with This integration provides a secure and versatile environment for processing payments using Webflow – especially for medical practices and online pharmacies that have been shut down by mainstream payment gateways like Stripe, Square, or PayPal. Alex Roy, CEO of Organic Payment Gateways, emphasized the company's interest in supporting this vital sector. "We've been listening to healthcare providers, online pharmacies, and telemedicine services – and more and more I hear about folks moving toward Webflow," Alex Roy stated. "It's clear that many are labeled high-risk and therefore struggling with payment processing, often getting flagged or shut down by the big names. I saw a real need there, and we're stepping up to make sure these essential businesses can focus on patient care, not payment gateway headaches." Alex Roy further highlighted the company's dedication to its clients. "Our approach has always been about genuine, one-on-one support. We're not just selling a service; we're building partnerships. We understand that every dollar counts for these businesses, which is why we're committed to offering a cost-effective solution, utilizing specifically underwritten health and pharmacy merchant accounts, payment software, and a tested, reliable third-party tool to ensure all the pieces work consistently and smoothly." Organic Payment Gateways' dedication to customer service is reflected in its 24/7 availability and its A+ rating from the Better Business Bureau, where it has been an accredited business since January 19, 2018. Organic Payment Gateways' BBB accreditation and reviews can be viewed at and additional customer feedback is available on Trustpilot at Healthcare providers interested in learning more about Organic Payment Gateways' Webflow-specific payment solutions can access comprehensive information at For a complete overview of payment processing options across the healthcare sector, visit About Organic Payment Gateways: Organic Payment Gateways is a leading provider of specialized credit card processing, merchant accounts, and payment gateway solutions. With a focus on industries often deemed high-risk or challenging by conventional processors, the company is dedicated to delivering reliable, secure, and affordable payment solutions tailored to the unique needs of its diverse clientele. Organic Payment Gateways prides itself on its personalized, USA-based customer service and commitment to fostering long-term business success. Learn more at Media Contact: Alex Roy 800-570-1347 396438@ View original content to download multimedia: SOURCE Organic Payment Gateways Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Avant Technologies Signs Letter of Intent for a Business Combination
Avant Technologies Signs Letter of Intent for a Business Combination

Yahoo

timean hour ago

  • Yahoo

Avant Technologies Signs Letter of Intent for a Business Combination

LAS VEGAS, June 10, 2025 /CNW/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), today announced that it has entered into a non-binding letter of intent ("LOI") for a potential business combination with Ainnova Tech, Inc. (Ainnova). Ainnova, the Company's joint venture partner, is a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI). Ainnova's technology portfolio includes its cutting-edge AI-powered platform technology, Vision AI, several key algorithms, and its proprietary automated retinal camera, which is currently in development. Under the terms of the LOI, Avant and Ainnova would become a combined entity, with Ainnova rolling 100% of its outstanding equity and equity equivalents—or all its business—into the combined public company, with the deal structure to be determined later by the parties based on further due diligence findings and other considerations. Avant and Ainnova expect to announce additional details regarding the business combination when a definitive agreement is executed, which is expected in late June or early next quarter. Any transaction would be subject to board and equity holder approval of both companies, regulatory approvals, and other customary conditions. Avant and Ainnova executives believe that now is the time to strengthen their partnership and merge into a single entity before the Company's pre-submission meeting with the U.S. Food and Drug Administration in early July, in preparation for the planned clinical trial of Ainnova's Vision AI platform for early detection of diabetic retinopathy. In late 2024, the two companies formed Ai-nova Acquisition Corp. (AAC) to advance and commercialize Ainnova's technology portfolio. During that time, the two companies completed further due diligence and focused on an opportunity to work together as one company. The Board of Directors and management team of Avant remain fully committed to executing the Company's strategic plan, which is focused on enhancing long-term value. Vinicio Vargas, Chief Executive Officer at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp., said of the business combination, "We believe bringing the two companies together will offer tremendous value for shareholders, it will simplify the process of advancing our technology to market, and it will deliver value to our customers and partners as we promote our technology portfolio globally. "We feel the joint venture has been a success and both companies have worked well together toward a common goal, so we believe that we can be even more successful and use our resources more effectively as one company to further AI in healthcare." About Ainnova Tech, Inc. Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI—our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions. About Avant Technologies, Inc. Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology. More information about Avant can be found at You can also follow us on social media at: Forward-Looking Statements Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release. Video: Contact: Avant Technologies, Inc. info@ View original content to download multimedia: SOURCE Avant Technologies Inc. View original content to download multimedia:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store